Search Results

You are looking at 81 - 90 of 2,919 items for :

  • Refine by Access: All x
Clear All
Full access

Care and Outcomes of Patients With Cancer Admitted to the Hospital on Weekends and Holidays: A Retrospective Cohort Study

Lauren Lapointe-Shaw, Hani Abushomar, Xi-Kuan Chen, Katerina Gapanenko, Chelsea Taylor, Monika K. Krzyzanowska, and Chaim M. Bell

measurement have been used to address this problem by clearly delineating best practices. 2 Although many improvement efforts have centered on the coordination of outpatient care services, there are few studies of in-hospital care processes and their outcomes

Full access

Patient-Reported Distress in Myelodysplastic Syndromes and Its Association With Clinical Outcomes: A Retrospective Cohort Study

Jesse D. Troy, Carlos M. de Castro, Mary Ruth Pupa, Greg P. Samsa, Amy P. Abernethy, and Thomas W. LeBlanc

distress has been associated with reduced survival in some cancers. 4 – 6 Myelodysplastic syndromes (MDS) are diagnosed primarily in older people and represent a diverse group of malignant bone marrow disorders with variable clinical outcome. 7 QOL is

Full access

Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study

Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt

using SPSS Statistics, version 25 (IBM Corp) and data analyses were performed with STATA, version 14.2 (StataCorp, LP). Explanatory and Outcome Measures The main explanatory variable was the therapy received. The outcome measure was the patients

Full access

Breast Cancer Diagnostics, Therapy, and Outcomes in Sub-Saharan Africa: A Population-Based Registry Study

Walburga Yvonne Joko-Fru, Mirko Griesel, Nikolaus Christian Simon Mezger, Lucia Hämmerl, Tobias Paul Seraphin, Jana Feuchtner, Henry Wabinga, Guy N’da, Assefa Mathewos, Bakarou Kamaté, Judith Nsonde Malanda, Freddy Houéhanou Rodrigue Gnangnon, Gladys Chebet Chesumbai, Anne Korir, Cesaltina Lorenzoni, Annelle Zietsman, Margaret Ziona Borok, Biying Liu, Christoph Thomssen, Paul McGale, Ahmedin Jemal, Donald Maxwell Parkin, and Eva Johanna Kantelhardt

using SPSS Statistics, version 25 (IBM Corp) and data analyses were performed with STATA, version 14.2 (StataCorp, LP). Explanatory and Outcome Measures The main explanatory variable was the therapy received. The outcome measure was the patients

Full access

Association Between Alcohol Use Disorder and Hospital Readmission Rates and Outcomes in Cancer Survivors: A Population Cohort Study

Jyun-Heng Lai, Sola Han, Chanhyun Park, and Anton L.V. Avanceña

without AUD. Unlike previous research on AUD and cancer survivors, this study focuses on short-term health care outcomes, such as readmission, that have been shown to predict longer-term outcomes, including mortality. 26 Findings from this study can

Full access

Impact of Recombinant Granulocyte Colony-Stimulating Factor During Neoadjuvant Therapy on Outcomes of Resected Pancreatic Cancer

Pranav Murthy, Mazen S. Zenati, Samer S. AlMasri, Annissa DeSilva, Aatur D. Singhi, Alessandro Paniccia, Kenneth K. Lee, Richard L. Simmons, Nathan Bahary, Michael T. Lotze, and Amer H. Zureikat

supportive G-CSF therapy in patients with PDAC to restore neutrophil counts, the impact of G-CSF administration during neoadjuvant therapy (NAT) on long-term outcomes is unclear. In this study, we sought to evaluate the impact of preoperative G

Full access

Novel Therapies Potentially Available for Pediatric B-Cell Non-Hodgkin Lymphoma

Paul D. Harker-Murray, Lauren Pommert, and Matthew J. Barth

-rituximab era, risk-stratified, response-based, multiagent chemotherapy included higher doses and additional cycles of chemotherapy for patients with higher-stage disease and resulted in cure rates ranging from 79% to 98% ( Table 1 ). Table 1. Outcomes for

Full access

Receipt of Screening Mammography by Insured Women Diagnosed With Breast Cancer and Impact on Outcomes

Marissa B. Lawson, Christoph I. Lee, Daniel S. Hippe, Shasank Chennupati, Catherine R. Fedorenko, Kathleen E. Malone, Scott D. Ramsey, and Janie M. Lee

breast cancers that can be treated with curative intent. 3 – 6 Many socioeconomic factors influence whether women participate in screening mammography and have the associated improved outcomes. 7 Lack of insurance coverage has been established as an

Full access

Real-World Outcomes of Patients With BRAF-Mutated Metastatic Colorectal Cancer Treated in the United States

Andrew Trunk, Matthew Braithwaite, Christopher Nevala-Plagemann, Lisa Pappas, Benjamin Haaland, and Ignacio Garrido-Laguna

the poor outcomes associated with BRAF mt mCRC. Although potential improvement in survival with FOLFOXIRI has been suggested, current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer (Version 4.2020) still do not give

Full access

Chemoradiotherapy Versus Chemotherapy Alone for Unresected Nonmetastatic Gallbladder Cancer: National Practice Patterns and Outcomes

Vivek Verma, Swati M. Surkar, Eric D. Brooks, Charles B. Simone II, and Chi Lin

study of a large, contemporary national database of a general US population aimed to evaluate national practice patterns and outcomes of unresected nonmetastatic GC receiving CT alone versus CRT. Although challenging to assess with single- or multi